The evolving role of PARP inhibitors in advanced ovarian cancer

[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin 2020;70(1):7–30. SiegelRL MillerKD JemalA Cancer statistics, 2020 CA Cancer J Clin 2020 70 1 7 30 10.3322/caac.2159031912902 Search in Google Scholar

[2] Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur Journal Cancer 2018. FerlayJ ColombetM SoerjomataramI DybaT RandiG BettioM Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018 Eur Journal Cancer 2018 10.1016/j.ejca.2018.07.00530100160 Search in Google Scholar

[3] Prat J, FIGO Committee on Gynecologic Oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 2014;124(1):1–5. PratJ FIGO Committee on Gynecologic Oncology Staging classification for cancer of the ovary, fallopian tube, and peritoneum Int J Gynaecol Obstet 2014 124 1 1 5 10.1016/j.ijgo.2013.10.00124219974 Search in Google Scholar

[4] Kubalanza K, Konecny GE. Mechanisms of PARP inhibitor resistance in ovarian cancer. Curr Opin Obstet Gynecol 2020;32(1):36–41. KubalanzaK KonecnyGE Mechanisms of PARP inhibitor resistance in ovarian cancer Curr Opin Obstet Gynecol 2020 32 1 36 41 10.1097/GCO.000000000000060031815769 Search in Google Scholar

[5] Macheret M, Halazonetis TD. DNA Replication Stress as a Hallmark of Cancer. Annu Rev Pathol 2015;10(1):425–48. MacheretM HalazonetisTD DNA Replication Stress as a Hallmark of Cancer Annu Rev Pathol 2015 10 1 425 48 10.1146/annurev-pathol-012414-04042425621662 Search in Google Scholar

[6] Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396(6712):643–9. LengauerC KinzlerKW VogelsteinB Genetic instabilities in human cancers Nature 1998 396 6712 643 9 10.1038/252929872311 Search in Google Scholar

[7] Graziani G, Szabó C. Clinical perspectives of PARP inhibitors. Pharmacol Res 2005;52(1):109–18. GrazianiG SzabóC Clinical perspectives of PARP inhibitors Pharmacol Res 2005 52 1 109 18 10.1016/j.phrs.2005.02.01315911339 Search in Google Scholar

[8] Lord CJ, Ashworth A. PARP inhibitors: Synthetic lethality in the clinic. Science 2017;355(6330):1152–8. LordCJ AshworthA PARP inhibitors: Synthetic lethality in the clinic Science 2017 355 6330 1152 8 10.1126/science.aam7344617505028302823 Search in Google Scholar

[9] Gibson BA, Kraus WL. New insights into the molecular and cellular functions of poly (ADP-ribose) and PARPs. Nat Rev Mol Cell Biol 2012;13(7):411–24. GibsonBA KrausWL New insights into the molecular and cellular functions of poly (ADP-ribose) and PARPs Nat Rev Mol Cell Biol 2012 13 7 411 24 10.1038/nrm337622713970 Search in Google Scholar

[10] Tangutoori S, Baldwin P, Sridhar S. PARP inhibitors: A new era of targeted therapy. Maturitas 2015;81(1):5–9. TangutooriS BaldwinP SridharS PARP inhibitors: A new era of targeted therapy Maturitas 2015 81 1 5 9 10.1016/j.maturitas.2015.01.01525708226 Search in Google Scholar

[11] Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434(7035):917–21. FarmerH McCabeN LordCJ TuttAN JohnsonDA RichardsonTB Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 2005 434 7035 917 21 10.1038/nature0344515829967 Search in Google Scholar

[12] Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434(7035):913–7. BryantHE SchultzN ThomasHD ParkerKM FlowerD LopezE Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 2005 434 7035 913 7 10.1038/nature0344315829966 Search in Google Scholar

[13] Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trap-ping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012;72(21):5588–99. MuraiJ HuangSY DasBB RenaudA ZhangY DoroshowJH Trap-ping of PARP1 and PARP2 by clinical PARP inhibitors Cancer Res 2012 72 21 5588 99 10.1158/0008-5472.CAN-12-2753352834523118055 Search in Google Scholar

[14] Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New Eng J Med 2012;366(15):1382–92. LedermannJ HarterP GourleyC FriedlanderM VergoteI RustinG Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer New Eng J Med 2012 366 15 1382 92 10.1056/NEJMoa110553522452356 Search in Google Scholar

[15] Telli ML, Timms KM, Reid J, Hennessy B, Mills GB, Jensen KC, et al: Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer. Clin Cancer Res 2016;22(15):3764–73. TelliML TimmsKM ReidJ HennessyB MillsGB JensenKC Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer Clin Cancer Res 2016 22 15 3764 73 10.1158/1078-0432.CCR-15-2477677342726957554 Search in Google Scholar

[16] Maya-Mendoza A, Moudry P, Merchut-Maya JM, Lee M, Strauss R, Bartek J, et al. High speed of fork progression induces DNA replication stress and genomic instability. Nature 2018;559(7713):279–84. Maya-MendozaA MoudryP Merchut-MayaJM LeeM StraussR BartekJ High speed of fork progression induces DNA replication stress and genomic instability Nature 2018 559 7713 279 84 10.1038/s41586-018-0261-529950726 Search in Google Scholar

[17] Ubhi T, Brown GW. Exploiting DNA Replication Stress for Cancer Treatment. Cancer Res 2019;79(8):1730–39. UbhiT BrownGW Exploiting DNA Replication Stress for Cancer Treatment Cancer Res 2019 79 8 1730 39 10.1158/0008-5472.CAN-18-363130967400 Search in Google Scholar

[18] Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361(2):123–34. FongPC BossDS YapTA TuttA WuP Mergui-RoelvinkM Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 2009 361 2 123 34 10.1056/NEJMoa090021219553641 Search in Google Scholar

[19] Moschetta M, George A, Kaye SB, Banerjee S. BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer. Ann Oncol 2016;27(8):1449–55. MoschettaM GeorgeA KayeSB BanerjeeS BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer Ann Oncol 2016 27 8 1449 55 10.1093/annonc/mdw14227037296 Search in Google Scholar

[20] da Cunha Colombo Bonadio RR, Fogace RN, Miranda VC, Diz MDPE. Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management. Clinics (Sao Paulo). 2018;73(suppl1):e450s. da Cunha Colombo BonadioRR FogaceRN MirandaVC DizMDPE Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management Clinics (Sao Paulo) 2018 73 suppl1 e450s 10.6061/clinics/2018/e450s609697730133561 Search in Google Scholar

[21] Hennessy BTJ, Timms KM, Carey MS, Gutin A, Meyer LA, Flake DD, et al. Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer. J Clin Oncol 2010;28(22):3570–6. HennessyBTJ TimmsKM CareyMS GutinA MeyerLA FlakeDD Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer J Clin Oncol 2010 28 22 3570 6 10.1200/JCO.2009.27.2997 Search in Google Scholar

[22] Amin N, Chaabouni N, George A. Genetic testing for epithelial ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2020;65:125–38. AminN ChaabouniN GeorgeA Genetic testing for epithelial ovarian cancer Best Pract Res Clin Obstet Gynaecol 2020 65 125 38 10.1016/j.bpobgyn.2020.01.005 Search in Google Scholar

[23] Pennington KP, Walsh T, Harrell MI, Lee MK, Pennil CC, Rendi MH, et al. Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas. Clin Cancer Res 2014;20(3):764–75. PenningtonKP WalshT HarrellMI LeeMK PennilCC RendiMH Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas Clin Cancer Res 2014 20 3 764 75 10.1158/1078-0432.CCR-13-2287 Search in Google Scholar

[24] Taniguchi T, Tischkowitz M, Ameziane N, Hodgson SV, Mathew CG, Joenje H, et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003;9(5):568–74. TaniguchiT TischkowitzM AmezianeN HodgsonSV MathewCG JoenjeH Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors Nat Med 2003 9 5 568 74 10.1038/nm852 Search in Google Scholar

[25] Cancer Genome Atlas Research Network. Integrated Genomic Analyses of Ovarian Carcinoma The Cancer Genome Atlas Research Network. Nature 2011;474(7353):609–15. Cancer Genome Atlas Research Network Integrated Genomic Analyses of Ovarian Carcinoma The Cancer Genome Atlas Research Network Nature 2011 474 7353 609 15 10.1038/nature10166 Search in Google Scholar

[26] Lupo B, Trusolino L. Inhibition of poly(ADP-ribosyl) ation in cancer: old and new paradigms revisited. Biochim Biophys Acta 2014;1846(1):201–15. LupoB TrusolinoL Inhibition of poly(ADP-ribosyl) ation in cancer: old and new paradigms revisited Biochim Biophys Acta 2014 1846 1 201 15 10.1016/j.bbcan.2014.07.004 Search in Google Scholar

[27] Yang HJ, Liu VW, Wang Y, Tsang PC, Ngan HY. Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data. BMC Cancer 2006;6:212. YangHJ LiuVW WangY TsangPC NganHY Differential DNA methylation profiles in gynecological cancers and correlation with clinico-pathological data BMC Cancer 2006 6 212 10.1186/1471-2407-6-212 Search in Google Scholar

[28] Brown LA, Irving J, Parker R, Kim H, Press JZ, Longacre TA, et al. Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas. Gynecol Oncol 2006;100(2):264–70. BrownLA IrvingJ ParkerR KimH PressJZ LongacreTA Amplification of EMSY, a novel oncogene on 11q13, in high grade ovarian surface epithelial carcinomas Gynecol Oncol 2006 100 2 264 70 10.1016/j.ygyno.2005.08.026 Search in Google Scholar

[29] Cousineau I, Belmaaza A. EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: Implications for chromosomal instability/recombination syndromes as checkpoint diseases. Mol Genet Genomics 2011;285(4):325–40. CousineauI BelmaazaA EMSY overexpression disrupts the BRCA2/RAD51 pathway in the DNA-damage response: Implications for chromosomal instability/recombination syndromes as checkpoint diseases Mol Genet Genomics 2011 285 4 325 40 10.1007/s00438-011-0612-5 Search in Google Scholar

[30] Hughes-Davies L, Huntsman D, Ruas M, Fuks F, Bye J, Chin SF, et al. EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer. Cell 2003;115(5):523–35. Hughes-DaviesL HuntsmanD RuasM FuksF ByeJ ChinSF EMSY links the BRCA2 pathway to sporadic breast and ovarian cancer Cell 2003 115 5 523 35 10.1016/S0092-8674(03)00930-9 Search in Google Scholar

[31] Norquist BM, Pennington KP, Agnew KJ, Harrell MI, Pennil CC, Lee MK, et al. Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing. Gynecol Oncol 2013;128(3):483–7. NorquistBM PenningtonKP AgnewKJ HarrellMI PennilCC LeeMK Characteristics of women with ovarian carcinoma who have BRCA1 and BRCA2 mutations not identified by clinical testing Gynecol Oncol 2013 128 3 483 7 10.1016/j.ygyno.2012.12.015391338223262210 Search in Google Scholar

[32] Norquist BM, Harrell MI, Brady MF, Walsh T, Lee MK, Gulsuner S, et al. Inherited mutations in women with ovarian carcinoma. JAMA Oncol 2016;2(4):482–90. NorquistBM HarrellMI BradyMF WalshT LeeMK GulsunerS Inherited mutations in women with ovarian carcinoma JAMA Oncol 2016 2 4 482 90 10.1001/jamaoncol.2015.5495484593926720728 Search in Google Scholar

[33] Norquist BM, Brady MF, Harrell MI, Walsh T, Lee MK, Gulsuner S, et al. Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: An NRG oncology/Gynecologic oncology group study. Clin Cancer Res 2018;24(4):777–83. NorquistBM BradyMF HarrellMI WalshT LeeMK GulsunerS Mutations in homologous recombination genes and outcomes in ovarian carcinoma patients in GOG 218: An NRG oncology/Gynecologic oncology group study Clin Cancer Res 2018 24 4 777 83 10.1158/1078-0432.CCR-17-1327581590929191972 Search in Google Scholar

[34] Constantinou P, Tischkowitz M. Genetics of gynaecological cancers. Best Pract Res Clin Obstet Gynaecol 2017;42:114–24. ConstantinouP TischkowitzM Genetics of gynaecological cancers Best Pract Res Clin Obstet Gynaecol 2017 42 114 24 10.1016/j.bpobgyn.2017.01.00428202331 Search in Google Scholar

[35] Ketabi Z, Bartuma K, Bernstein I, Malander S, Grönberg H, Björck E, et al. Ovarian cancer linked to lynch syndrome typically presents as early-onset, non-serous epithelial tumors. Gynecol Oncol 2011;121(3):462–5. KetabiZ BartumaK BernsteinI MalanderS GrönbergH BjörckE Ovarian cancer linked to lynch syndrome typically presents as early-onset, non-serous epithelial tumors Gynecol Oncol 2011 121 3 462 5 10.1016/j.ygyno.2011.02.01021388660 Search in Google Scholar

[36] Kim G, Iso G, McKee AE, Zhang H, Tang S, Gwise T, et al. FDA Approval Summary: Olaparib Monotherapy in Patients With Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated With Three or More Lines of Chemotherapy. Clin Cancer Res 2015;21(19):4257–61. KimG IsoG McKeeAE ZhangH TangS GwiseT FDA Approval Summary: Olaparib Monotherapy in Patients With Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated With Three or More Lines of Chemotherapy Clin Cancer Res 2015 21 19 4257 61 10.1158/1078-0432.CCR-15-088726187614 Search in Google Scholar

[37] Bundred N, Gardovskis J, Jaskiewicz J, Eglitis J, Paramonov V, McCormack P, et al. Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery. Invest New Drugs 2013;31:949–58. BundredN GardovskisJ JaskiewiczJ EglitisJ ParamonovV McCormackP Evaluation of the pharmacodynamics and pharmacokinetics of the PARP inhibitor olaparib: a Phase I multicentre trial in patients scheduled for elective breast cancer surgery Invest New Drugs 2013 31 949 58 10.1007/s10637-012-9922-723315029 Search in Google Scholar

[38] Sun K, Mikule K, Wang Z, Poon G, Vaidyanathan A, Smith G, et al. A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models. Oncotarget 2018;9(98):37080–96. SunK MikuleK WangZ PoonG VaidyanathanA SmithG A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models Oncotarget 2018 9 98 37080 96 10.18632/oncotarget.26354632468930647846 Search in Google Scholar

[39] Liao M, Watkins S, Nash E, Isaacson J, Etter J, Beltman J, et al. Evaluation of absorption, distribution, metabolism, and excretion of [¹⁴C]-rucaparib, a poly (ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors. Invest New Drugs 2020;38(3):765–75. LiaoM WatkinsS NashE IsaacsonJ EtterJ BeltmanJ Evaluation of absorption, distribution, metabolism, and excretion of [¹⁴C]-rucaparib, a poly (ADP-ribose) polymerase inhibitor, in patients with advanced solid tumors Invest New Drugs 2020 38 3 765 75 10.1007/s10637-019-00815-2721119331250355 Search in Google Scholar

[40] Thorsell AG, Ekblad T, Karlberg T, Löw M, Pinto AF, Trésaugues L, et al. Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors. J Med Chem 2017;60(4):1262–71. ThorsellAG EkbladT KarlbergT LöwM PintoAF TrésauguesL Structural Basis for Potency and Promiscuity in Poly(ADP-ribose) Polymerase (PARP) and Tankyrase Inhibitors J Med Chem 2017 60 4 1262 71 10.1021/acs.jmedchem.6b00990593427428001384 Search in Google Scholar

[41] van Andel L, Zhang Z, Lu S, Kansra V, Agarwal S, Hughes L, et al. Human mass balance study and metabolite profiling of ¹⁴C–niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer. Investig New Drugs 2017;35(6):751–65. van AndelL ZhangZ LuS KansraV AgarwalS HughesL Human mass balance study and metabolite profiling of ¹⁴C–niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer Investig New Drugs 2017 35 6 751 65 10.1007/s10637-017-0451-2 Search in Google Scholar

[42] Werner TL, Sachdev J, Swisher EM, Gutierrez M, Kittaneh M, Stein MN, et al. Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study. Cancer Med 2018;7(6):2360–9. WernerTL SachdevJ SwisherEM GutierrezM KittanehM SteinMN Safety and pharmacokinetics of veliparib extended-release in patients with advanced solid tumors: a phase I study Cancer Med 2018 7 6 2360 9 10.1002/cam4.1488 Search in Google Scholar

[43] Li J, Kim S, Sha X, Wiegand R, Wu J, LoRusso P. Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics. Clin Cancer Res 2014;20:3931–44. LiJ KimS ShaX WiegandR WuJ LoRussoP Complex disease-, gene-, and drug-drug interactions: impacts of renal function, CYP2D6 phenotype, and OCT2 activity on veliparib pharmacokinetics Clin Cancer Res 2014 20 3931 44 10.1158/1078-0432.CCR-14-0791 Search in Google Scholar

[44] de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, et al. Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers. Cancer Discov 2017;7:620–9. de BonoJ RamanathanRK MinaL ChughR GlaspyJ RafiiS Phase I, dose-escalation, two-part trial of the PARP inhibitor talazoparib in patients with advanced germline BRCA1/2 mutations and selected sporadic cancers Cancer Discov 2017 7 620 9 10.1158/2159-8290.CD-16-1250 Search in Google Scholar

[45] US Food and Drug Administration. Lynparza prescribing information (2017. Update). 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208558s000lbl.pdf US Food and Drug Administration Lynparza prescribing information (2017. Update) 2014 https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208558s000lbl.pdf Search in Google Scholar

[46] Hopkins TA, Shi Y, Rodriguez LE, Solomon LR, Donawho CK, DiGiammarino EL, et al. Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors. Mol Cancer Res 2015;13:1465–77. HopkinsTA ShiY RodriguezLE SolomonLR DonawhoCK DiGiammarinoEL Mechanistic dissection of PARP1 trapping and the impact on in vivo tolerability and efficacy of PARP inhibitors Mol Cancer Res 2015 13 1465 77 10.1158/1541-7786.MCR-15-0191-T Search in Google Scholar

[47] Hopkins TA, Ainsworth WB, Ellis PA, Donawho CK, DiGiammarino EL, Panchal SC, et al. PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow. Mol Cancer Res 2019;17(2):409–19. HopkinsTA AinsworthWB EllisPA DonawhoCK DiGiammarinoEL PanchalSC PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow Mol Cancer Res 2019 17 2 409 19 10.1158/1541-7786.MCR-18-0138 Search in Google Scholar

[48] Plummer R, Swaisland H, Leunen K, van Herpen CM, Jerusalem G, De Grève J, et al. Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours. Cancer Chemother Pharmacol 2015;76(4):723–9. PlummerR SwaislandH LeunenK van HerpenCM JerusalemG De GrèveJ Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumours Cancer Chemother Pharmacol 2015 76 4 723 9 10.1007/s00280-015-2836-2 Search in Google Scholar

[49] Zhou D, Li J, Bui K, Learoyd M, Berges A, Milenkova T, et al. Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients. Clin Pharmacokinet 2019;58(5):615–25. ZhouD LiJ BuiK LearoydM BergesA MilenkovaT Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology Patients Clin Pharmacokinet 2019 58 5 615 25 10.1007/s40262-018-0714-x Search in Google Scholar

[50] Pujade-Lauraine E, Ledermann JA, Selle F, Gebski V, Penson RT, Oza AM, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomized, placebo-controlled, phase 3 trial. Lancet Oncol 2017;18(9):1274–84. Pujade-LauraineE LedermannJA SelleF GebskiV PensonRT OzaAM Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomized, placebo-controlled, phase 3 trial Lancet Oncol 2017 18 9 1274 84 10.1016/S1470-2045(17)30469-2 Search in Google Scholar

[51] Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial. Lancet 2010;376(9737):245–51. AudehMW CarmichaelJ PensonRT FriedlanderM PowellB Bell-McGuinnKM Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: A proof-of-concept trial Lancet 2010 376 9737 245 51 10.1016/S0140-6736(10)60893-8 Search in Google Scholar

[52] Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, et al. Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 2012;30(4):372–9. KayeSB LubinskiJ MatulonisU AngJE GourleyC KarlanBY Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer J Clin Oncol 2012 30 4 372 9 10.1200/JCO.2011.36.9215 Search in Google Scholar

[53] Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, et al. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol 2014;15(8):852–61. LedermannJ HarterP GourleyC FriedlanderM VergoteI RustinG Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial Lancet Oncol 2014 15 8 852 61 10.1097/OGX.0000000000000107 Search in Google Scholar

[54] Friedlander M, Matulonis U, Gourley C, du Bois A, Vergote I, Rustin G, et al. Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy. Br J Cancer 2018;119(9):1075–85. FriedlanderM MatulonisU GourleyC du BoisA VergoteI RustinG Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy Br J Cancer 2018 119 9 1075 85 10.1038/s41416-018-0271-y Search in Google Scholar

[55] Domchek SM, Aghajanian C, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, et al. Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy. Gynecol Oncol 2016;140(2):199–203. DomchekSM AghajanianC Shapira-FrommerR SchmutzlerRK AudehMW FriedlanderM Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy Gynecol Oncol 2016 140 2 199 203 10.1016/j.ygyno.2015.12.020 Search in Google Scholar

[56] Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, et al. Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation. J Clin Oncol 2015;33(3):244–50. KaufmanB Shapira-FrommerR SchmutzlerRK AudehMW FriedlanderM BalmañaJ Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation J Clin Oncol 2015 33 3 244 50 10.1200/JCO.2014.56.2728 Search in Google Scholar

[57] Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, et al. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study. Lancet Oncol 2011;12(9):852–61. GelmonKA TischkowitzM MackayH SwenertonK RobidouxA TonkinK Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: A phase 2, multicentre, open-label, non-randomised study Lancet Oncol 2011 12 9 852 61 10.1016/S1470-2045(11)70214-5 Search in Google Scholar

[58] Dougherty BA, Lai Z, Hodgson DR, Orr MCM, Hawryluk M, Sun J, et al. Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in highgrade serous ovarian cancers in the maintenance setting. Oncotarget 2017;8(27):43653–61. DoughertyBA LaiZ HodgsonDR OrrMCM HawrylukM SunJ Biological and clinical evidence for somatic mutations in BRCA1 and BRCA2 as predictive markers for olaparib response in highgrade serous ovarian cancers in the maintenance setting Oncotarget 2017 8 27 43653 61 10.18632/oncotarget.17613554643128525389 Search in Google Scholar

[59] Ledermann JA, Pujade-Lauraine E. Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer. Ther Adv Med Oncol 2019; 11:1758835919849753. LedermannJA Pujade-LauraineE Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer Ther Adv Med Oncol 2019 11 1758835919849753 10.1177/1758835919849753653575431205507 Search in Google Scholar

[60] Olaparib makes OS gains in Ovarian Cancer. Cancer Discov 2020;10(7): OF3. Olaparib makes OS gains in Ovarian Cancer Cancer Discov 2020 10 7 OF3 10.1158/2159-8290.CD-NB2020-04832471872 Search in Google Scholar

[61] Moore K, Colombo N, Scambia G, Kim BG, Oaknin A, Friedlander M, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med 2018;379(26):2495–505. MooreK ColomboN ScambiaG KimBG OakninA FriedlanderM Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer N Engl J Med 2018 379 26 2495 505 10.1056/NEJMoa181085830345884 Search in Google Scholar

[62] Penson RT, Valencia RV, Cibula D, Colombo N, Leath CA, Bidziński M, et al. Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial. J Clin Oncol 2020;38(11):1164–74. PensonRT ValenciaRV CibulaD ColomboN LeathCA BidzińskiM Olaparib Versus Nonplatinum Chemotherapy in Patients With Platinum-Sensitive Relapsed Ovarian Cancer and a Germline BRCA1/2 Mutation (SOLO3): A Randomized Phase III Trial J Clin Oncol 2020 38 11 1164 74 10.1200/JCO.19.02745 Search in Google Scholar

[63] Vanderstichele A, Van Nieuwenhuysen E, Han S, Concin N, Van Gorp T, Berteloot P, et al. Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer. J Clin Oncol 2019;37(15_suppl). Abstract 5507. VandersticheleA Van NieuwenhuysenE HanS ConcinN Van GorpT BertelootP Randomized phase II CLIO study on olaparib monotherapy versus chemotherapy in platinum-resistant ovarian cancer J Clin Oncol 2019 37 15_suppl Abstract 5507 10.1200/JCO.2019.37.15_suppl.5507 Search in Google Scholar

[64] Knezevic CE, Wright G, Rix LLR, Kim W, Kuenzi BM, Luo Y, et al. Proteome-wide profiling of clinical PARP inhibitors reveals compound-specific secondary targets. Cell Chem Biol 2016;23(12):1490–1503. KnezevicCE WrightG RixLLR KimW KuenziBM LuoY Proteome-wide profiling of clinical PARP inhibitors reveals compound-specific secondary targets Cell Chem Biol 2016 23 12 1490 1503 10.1016/j.chembiol.2016.10.011 Search in Google Scholar

[65] Wilson RH, Evans TJ, Middleton MR, Molife LR, Spicer J, Dieras V, et al. A Phase I Study of Intravenous and Oral Rucaparib in Combination With Chemotherapy in Patients With Advanced Solid Tumours. Br J Cancer 2017:116(7):884–92. WilsonRH EvansTJ MiddletonMR MolifeLR SpicerJ DierasV A Phase I Study of Intravenous and Oral Rucaparib in Combination With Chemotherapy in Patients With Advanced Solid Tumours Br J Cancer 2017 116 7 884 92 10.1038/bjc.2017.36 Search in Google Scholar

[66] Shapiro GI, Kristeleit RS, Burris HA, LoRusso P, Patel MR, Drew H, et al. Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors. Clin Pharmacol Drug Dev 2019;8(1):107–118. ShapiroGI KristeleitRS BurrisHA LoRussoP PatelMR DrewH Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors Clin Pharmacol Drug Dev 2019 8 1 107 118 10.1002/cpdd.575 Search in Google Scholar

[67] Parrish K, Cen L, Murray J, Calligaris D, Kizilbash S, Mittapalli RK, et al. Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System. Mol Cancer Ther 2015;14(12): 2735–43. ParrishK CenL MurrayJ CalligarisD KizilbashS MittapalliRK Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System Mol Cancer Ther 2015 14 12 2735 43 10.1158/1535-7163.MCT-15-0553 Search in Google Scholar

[68] Dumus S, Sparidans RW, van Esch A, Wagennar E, Beijnen JH, Schinkel AH. Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699). Pharm Res 2015;32:37–46. DumusS SparidansRW van EschA WagennarE BeijnenJH SchinkelAH Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699) Pharm Res 2015 32 37 46 10.1007/s11095-014-1442-z Search in Google Scholar

[69] Kristeleit RS, Shapiro GI, Burris HA, Oza AM, LoRusso P, Patel MR, et al. A phase I–II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors. Clin Cancer Res 2017;23(15):4095–106. KristeleitRS ShapiroGI BurrisHA OzaAM LoRussoP PatelMR A phase I–II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors Clin Cancer Res 2017 23 15 4095 106 10.1158/1078-0432.CCR-16-2796 Search in Google Scholar

[70] Drew Y, Ledermann J, Hall G, Rea D, Glasspool R, Highley M, et al. Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer. Br J Cancer 2016;114(12):e21. DrewY LedermannJ HallG ReaD GlasspoolR HighleyM Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer Br J Cancer 2016 114 12 e21 10.1038/bjc.2016.133 Search in Google Scholar

[71] Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol 2017;18(1):75–87. SwisherEM LinKK OzaAM ScottCL GiordanoH SunJ Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial Lancet Oncol 2017 18 1 75 87 10.1016/S1470-2045(16)30559-9 Search in Google Scholar

[72] Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, et al. Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2. Gynecol Oncol 2017;147(2):267–75. OzaAM TinkerAV OakninA Shapira-FrommerR McNeishIA SwisherEM Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2 Gynecol Oncol 2017 147 2 267 75 10.1016/j.ygyno.2017.08.022 Search in Google Scholar

[73] Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2017;390(10106):1949–61. ColemanRL OzaAM LorussoD AghajanianC OakninA DeanA Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet 2017 390 10106 1949 61 10.1016/S0140-6736(17)32440-6 Search in Google Scholar

[74] Zhang Z-Y, Kansra V, van Andel L, Tibben M, Rosing H, Lu S, et al. Characterization of absorption, metabolism, and elimination of Niraparib, an investigational poly (ADP-ribose) polymerase inhibitor, in cancer patients. Clin Ther 2017;39(8-suppl):e7–8. ZhangZ-Y KansraV van AndelL TibbenM RosingH LuS Characterization of absorption, metabolism, and elimination of Niraparib, an investigational poly (ADP-ribose) polymerase inhibitor, in cancer patients Clin Ther 2017 39 8-suppl e7 8 10.1016/j.clinthera.2017.05.025 Search in Google Scholar

[75] Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, et al. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: A phase 1 dose-escalation trial. Lancet Oncol 2013;14(9):882–92. SandhuSK SchelmanWR WildingG MorenoV BairdRD MirandaS The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: A phase 1 dose-escalation trial Lancet Oncol 2013 14 9 882 92 10.1016/S1470-2045(13)70240-7 Search in Google Scholar

[76] Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, et al. Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med 2016;375(22):2154–64. MirzaMR MonkBJ HerrstedtJ OzaAM MahnerS RedondoA Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer N Engl J Med 2016 375 22 2154 64 10.1056/NEJMoa1611310 Search in Google Scholar

[77] Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, et al. Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial. J Clin Oncol 2019;37(32):2968–73. Del CampoJM MatulonisUA MalanderS ProvencherD MahnerS FollanaP Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16/NOVA trial J Clin Oncol 2019 37 32 2968 73 10.1200/JCO.18.02238 Search in Google Scholar

[78] Jiang X, Li W, Li X, Bai H, Zhang Z. Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer. Cancer Manag Res 2019;11:4371–90. JiangX LiW LiX BaiH ZhangZ Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer Cancer Manag Res 2019 11 4371 90 10.2147/CMAR.S200524 Search in Google Scholar

[79] González-Martín A, Pothuri B, Vergote I, DePont Christensen R, Graybill W, Mirza MR, et al. Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med 2019;381(25):2391–402. González-MartínA PothuriB VergoteI DePont ChristensenR GraybillW MirzaMR Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer N Engl J Med 2019 381 25 2391 402 10.1056/NEJMoa1910962 Search in Google Scholar

[80] Moore KN, Secord AA, Geller MA, Miller DS, Cloven N, Fleming GF, et al. Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 2019;20(5):636–48. MooreKN SecordAA GellerMA MillerDS ClovenN FlemingGF Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial Lancet Oncol 2019 20 5 636 48 10.1016/S1470-2045(19)30029-4 Search in Google Scholar

[81] Murai J, Huang SN, Renaud A, Zhang Y, Ji J, Takeda S, et al. Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther 2014;13(2):433–43. MuraiJ HuangSN RenaudA ZhangY JiJ TakedaS Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib Mol Cancer Ther 2014 13 2 433 43 10.1158/1535-7163.MCT-13-0803394606224356813 Search in Google Scholar

[82] Kizilbash SH, Gupta SK, Chang K, Kawashima R, Parrish KE, Carlson BL, et al. Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma. Mol Cancer Ther 2017;16(12):2735–46. KizilbashSH GuptaSK ChangK KawashimaR ParrishKE CarlsonBL Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma Mol Cancer Ther 2017 16 12 2735 46 10.1158/1535-7163.MCT-17-0365571690228947502 Search in Google Scholar

[83] Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, et al. BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res 2013;19:5003–15. ShenY RehmanFL FengY BoshuizenJ BajramiI ElliottR BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency Clin Cancer Res 2013 19 5003 15 10.1158/1078-0432.CCR-13-1391648544923881923 Search in Google Scholar

[84] BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment. https://clinicaltrials.gov/ct2/show/NCT02326844. Accessed 29 Nov 2019. BMN 673 (Talazoparib), an Oral PARP Inhibitor, in People With Deleterious BRCA1/2 Mutation-Associated Ovarian Cancer Who Have Had Prior PARP Inhibitor Treatment https://clinicaltrials.gov/ct2/show/NCT02326844. Accessed 29 Nov 2019. Search in Google Scholar

[85] Nuthalapati S, Munasinghe W, Giranda V, Xiong H. Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination With Temozolomide in Subjects With Nonhematologic Malignancies. Clin Pharmacokinet 2018;57(1):51–8. NuthalapatiS MunasingheW GirandaV XiongH Clinical Pharmacokinetics and Mass Balance of Veliparib in Combination With Temozolomide in Subjects With Nonhematologic Malignancies Clin Pharmacokinet 2018 57 1 51 8 10.1007/s40262-017-0547-z28497258 Search in Google Scholar

[86] Tawbi HAH, Chu E, Lin Y, Hyman DM, Goel S, Rudek MA, et al. Early phase I study of the PARP inhibitor veliparib (ABT-888) alone or in combination with carboplatin/paclitaxel (CP) in patients with varying degrees of hepatic or renal dysfunction: A study of the NCI-Organ Dysfunction Working Group (ODG). J Clin Oncol 2014;32(15_suppl):2572. TawbiHAH ChuE LinY HymanDM GoelS RudekMA Early phase I study of the PARP inhibitor veliparib (ABT-888) alone or in combination with carboplatin/paclitaxel (CP) in patients with varying degrees of hepatic or renal dysfunction: A study of the NCI-Organ Dysfunction Working Group (ODG) J Clin Oncol 2014 32 15_suppl 2572 10.1200/jco.2014.32.15_suppl.2572 Search in Google Scholar

[87] Steffensen KD, Adimi P, Jakobsen A. Veliparib monotherapy to patients with BRCA germ line mutation and platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer: A phase I/II study. Int J Gynecol Cancer 2017;27(9):1842–9. SteffensenKD AdimiP JakobsenA Veliparib monotherapy to patients with BRCA germ line mutation and platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer: A phase I/II study Int J Gynecol Cancer 2017 27 9 1842 9 10.1097/IGC.000000000000108928763368 Search in Google Scholar

[88] Armstrong DK, Moore KN, Miller A, Bell-McGuinn KM, Schilder RJ, Fracasso PM, et al. A phase I study of veliparib incorporated into front-line platinum based cheotherpy and bevacizumab in epithelial ovarian cancer (NCT00989651): A GOG/nrg trial. J Clin Oncol 2019;37(15_suppl):5523. ArmstrongDK MooreKN MillerA Bell-McGuinnKM SchilderRJ FracassoPM A phase I study of veliparib incorporated into front-line platinum based cheotherpy and bevacizumab in epithelial ovarian cancer (NCT00989651): A GOG/nrg trial J Clin Oncol 2019 37 15_suppl 5523 10.1200/JCO.2019.37.15_suppl.5523 Search in Google Scholar

[89] Coleman RL, Sill MW, Bell-Mcguinn K, Aghajanian C, Gray HJ, Tewari KS, et al. A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol 2015;137(3):386–91. ColemanRL SillMW Bell-McguinnK AghajanianC GrayHJ TewariKS A phase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - An NRG Oncology/Gynecologic Oncology Group study Gynecol Oncol 2015 137 3 386 91 10.1016/j.ygyno.2015.03.042444752525818403 Search in Google Scholar

[90] Wang L, Yang C, Xie C, Jiang J, Gao M, Fu L, et al. Pharmacologic characterization of fluzoparib, a novel poly (ADP ribose) polymerase inhibitor undergoing clinical trials. Cancer Sci 2019;110(3):1064–75. WangL YangC XieC JiangJ GaoM FuL Pharmacologic characterization of fluzoparib, a novel poly (ADP ribose) polymerase inhibitor undergoing clinical trials Cancer Sci 2019 110 3 1064 75 10.1111/cas.13947639888030663191 Search in Google Scholar

[91] Li H, Liu R, Shao B, Ran R, Song G, Wang K, et al. Phase I dose-escalation and expansion study of the PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumours. Clin J Cancer Res 2020;32(3):370–383. LiH LiuR ShaoB RanR SongG WangK Phase I dose-escalation and expansion study of the PARP inhibitor, fluzoparib (SHR3162), in patients with advanced solid tumours Clin J Cancer Res 2020 32 3 370 383 10.1093/annonc/mdz242.040 Search in Google Scholar

[92] Gupta SK, Carlson BL, Schroeder MA, Bakken KK, Tuma AC, Sarkaria JN. Inhibition of PARP activity by BGB-290 potentiates efficacy of temozolomide in patient derived xenografts of glioblastoma multiforme. Cancer Res 2015;75 (suppl 15):3505. GuptaSK CarlsonBL SchroederMA BakkenKK TumaAC SarkariaJN Inhibition of PARP activity by BGB-290 potentiates efficacy of temozolomide in patient derived xenografts of glioblastoma multiforme Cancer Res 2015 75 suppl 15 3505 10.1158/1538-7445.AM2015-3505 Search in Google Scholar

[93] Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer. https://clinicaltrials.gov/ct2/show/NCT03519230 Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer https://clinicaltrials.gov/ct2/show/NCT03519230 Search in Google Scholar

[94] Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy (PRECISE). https://clinicaltrials.gov/ct2/show/NCT03933761 Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy (PRECISE) https://clinicaltrials.gov/ct2/show/NCT03933761 Search in Google Scholar

[95] McGonigle S, Chen Z, Wu J, Chang P, Kolber-Simonds D, et al. E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling. Oncotarget. 2015;6(38):41307–23. McGonigleS ChenZ WuJ ChangP Kolber-SimondsD E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling Oncotarget 2015 6 38 41307 23 10.18632/oncotarget.5846474740726513298 Search in Google Scholar

[96] Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP® (PREDICT 2X-121). https://clinicaltrials.gov/ct2/show/NCT03878849 Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP® (PREDICT 2X-121) https://clinicaltrials.gov/ct2/show/NCT03878849 Search in Google Scholar

[97] Veneris JT, Matulonis UA, Liu JF, Konstantinopoulos PA. Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations. Gnecol Oncol 2020;156(2):488–97. VenerisJT MatulonisUA LiuJF KonstantinopoulosPA Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations Gnecol Oncol 2020 156 2 488 97 10.1016/j.ygyno.2019.09.02131630846 Search in Google Scholar

[98] Oza AM, Cibula D, Oaknin A, Poole CJ, Mathijssen RHJ, Gabe S, et al. Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSC SOC): A randomized, open-label phase II study. JCO 2012;30(15):5001. OzaAM CibulaD OakninA PooleCJ MathijssenRHJ GabeS Olaparib plus paclitaxel plus carboplatin (P/C) followed by olaparib maintenance treatment in patients (pts) with platinum-sensitive recurrent serous ovarian cancer (PSC SOC): A randomized, open-label phase II study JCO 2012 30 15 5001 10.1200/jco.2012.30.15_suppl.5001 Search in Google Scholar

[99] Del Conte G, Sessa C, von Moos R, Vigano L, Digena T, Locatelli A, et al. Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours. BJC 2014;111:651–9. Del ConteG SessaC von MoosR ViganoL DigenaT LocatelliA Phase I study of olaparib in combination with liposomal doxorubicin in patients with advanced solid tumours BJC 2014 111 651 9 10.1038/bjc.2014.345413449825025963 Search in Google Scholar

[100] Perez-Fidalgo JA, Iglesias M, Bohn U, Calvo E, Garcia Y, Guerra E, et al. GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer. Future Sci OA. 2019;5(2):FSO370. Perez-FidalgoJA IglesiasM BohnU CalvoE GarciaY GuerraE GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer Future Sci OA 2019 5 2 FSO370 10.4155/fsoa-2018-0107639162430820349 Search in Google Scholar

[101] Rivkin SE, Moon J, Iriarte DS, Bailey E, Sloan HL, Goodman GE, et al. Phase Ib with expansion study of olaparib plus weekly (Metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients. Int J Gynecol Cancer 2019;(online). RivkinSE MoonJ IriarteDS BaileyE SloanHL GoodmanGE Phase Ib with expansion study of olaparib plus weekly (Metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients Int J Gynecol Cancer 2019 (online) 10.1136/ijgc-2018-00003530700568 Search in Google Scholar

[102] Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, et al. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clin Cancer Res 2017;23(21):6400–10. DhawanMS BartelinkIH AggarwalRR LengJ ZhangJZ PawlowskaN Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors Clin Cancer Res 2017 23 21 6400 10 10.1158/1078-0432.CCR-17-070328790114 Search in Google Scholar

[103] Schafer ES, Rau RE, Berg SL, Liu X, Minard CG, Bishop AJR, et al. Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411). Pediatr Blood Cancer 2020;67(2):e28073. SchaferES RauRE BergSL LiuX MinardCG BishopAJR Phase 1/2 trial of talazoparib in combination with temozolomide in children and adolescents with refractory/recurrent solid tumors including Ewing sarcoma: A Children's Oncology Group Phase 1 Consortium study (ADVL1411) Pediatr Blood Cancer 2020 67 2 e28073 10.1002/pbc.2807331724813 Search in Google Scholar

[104] Coleman RL, Fleming GF, Brady MF, Swisher EM, Steffensen KD, Friedlander M, et al. Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer. N Engl J Med 2019;381(25):2403–15. ColemanRL FlemingGF BradyMF SwisherEM SteffensenKD FriedlanderM Veliparib with first-line chemotherapy and as maintenance therapy in ovarian cancer N Engl J Med 2019 381 25 2403 15 10.1056/NEJMoa1909707694143931562800 Search in Google Scholar

[105] LoRusso PM, Li J, Burger A, Heilbrun LK, Sausville EA, Boerner SA, et al. Phase I safety, pharmacokinetic, and pharmacodynamic study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors. Clin Cancer Res 2016;22:3227–37. LoRussoPM LiJ BurgerA HeilbrunLK SausvilleEA BoernerSA Phase I safety, pharmacokinetic, and pharmacodynamic study of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib (ABT-888) in combination with irinotecan in patients with advanced solid tumors Clin Cancer Res 2016 22 3227 37 10.1158/1078-0432.CCR-15-0652493071026842236 Search in Google Scholar

[106] Wahner Hendrickson AE, Menefee ME, Hartmann LC, Long HJ, Northfelt DW, Reid JM, et al. A phase I clinical trial of the poly(ADP-ribose) polymerase inhibitor veliparib and weekly topotecan in patients with solid tumors. Clin Cancer Res 2018;24(4):744–52. Wahner HendricksonAE MenefeeME HartmannLC LongHJ NorthfeltDW ReidJM A phase I clinical trial of the poly(ADP-ribose) polymerase inhibitor veliparib and weekly topotecan in patients with solid tumors Clin Cancer Res 2018 24 4 744 52 10.1158/1078-0432.CCR-17-1590 Search in Google Scholar

[107] Hjortkjær M, Kanstrup H, Jakobsen A, Steffensen KD. Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status. Cancer Treat Res Commun 2018;14:7–12. HjortkjærM KanstrupH JakobsenA SteffensenKD Veliparib and topotecan for patients with platinum-resistant or partially platinum-sensitive relapse of epithelial ovarian cancer with BRCA negative or unknown BRCA status Cancer Treat Res Commun 2018 14 7 12 10.1016/j.ctarc.2017.09.001 Search in Google Scholar

[108] Gray HJ, Bell-McGuinn K, Fleming GF, Cristea M, Xiong H, Sullivan D, et al. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies. Gynecol Oncol 2018;148(3):507–14. GrayHJ Bell-McGuinnK FlemingGF CristeaM XiongH SullivanD Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies Gynecol Oncol 2018 148 3 507 14 10.1016/j.ygyno.2017.12.029 Search in Google Scholar

[109] Keiss KA, Herman JM, Armstrong D, Zahurak M, Fyles A, Brade A, et al. A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers. Gynecol Oncol 2017;144(3):486–90. KeissKA HermanJM ArmstrongD ZahurakM FylesA BradeA A final report of a phase I study of veliparib (ABT-888) in combination with low-dose fractionated whole abdominal radiation therapy (LDFWAR) in patients with advanced solid malignancies and peritoneal carcinomatosis with a dose escalation in ovarian and fallopian tube cancers Gynecol Oncol 2017 144 3 486 90 10.1016/j.ygyno.2017.01.016 Search in Google Scholar

[110] Liu JF, Tolaney SM, Birrer M, Fleming GF, Buss MK, Dahlberg SE, et al. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer 2013;49(14):2972–8. LiuJF TolaneySM BirrerM FlemingGF BussMK DahlbergSE A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer Eur J Cancer 2013 49 14 2972 8 10.1016/j.ejca.2013.05.020 Search in Google Scholar

[111] Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, et al. Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: A randomised phase 2 study. Lancet Oncol 2014;15(11):1207–14. LiuJF BarryWT BirrerM LeeJM BuckanovichRJ FlemingGF Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: A randomised phase 2 study Lancet Oncol 2014 15 11 1207 14 10.1016/S1470-2045(14)70391-2 Search in Google Scholar

[112] Liu JF, Barry WT, Wenham RM, Wahner Hendrickson AE, Armstrong DK, et al. A phase 2 biomarker trial of combination cediranib and Olaparib in relapsed platinum sensitive and platinum resistant ovarian cancer. JCO 2018;36(15_suppl):5519. LiuJF BarryWT WenhamRM Wahner HendricksonAE ArmstrongDK A phase 2 biomarker trial of combination cediranib and Olaparib in relapsed platinum sensitive and platinum resistant ovarian cancer JCO 2018 36 15_suppl 5519 10.1200/JCO.2018.36.15_suppl.5519 Search in Google Scholar

[113] Liu JF, Barry WT, Birrer M, Lee JM, Buckanovich RJ, Fleming GF, et al. Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer. Ann Oncol 2019;30(4):551–7. LiuJF BarryWT BirrerM LeeJM BuckanovichRJ FlemingGF Overall survival and updated progression-free survival outcomes in a randomized phase II study of combination cediranib and olaparib versus olaparib in relapsed platinum-sensitive ovarian cancer Ann Oncol 2019 30 4 551 7 10.1093/annonc/mdz018650362830753272 Search in Google Scholar

[114] Liu JF, Brady MF, Matulonis UA, Miller A, Kohn EC, Swisher EM, et al. A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer. JCO 2020;38(15_Suppl):6003. LiuJF BradyMF MatulonisUA MillerA KohnEC SwisherEM A phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in recurrent platinum-sensitive ovarian cancer JCO 2020 38 15_Suppl 6003 10.1200/JCO.2020.38.15_suppl.6003 Search in Google Scholar

[115] Ray-Coquard I, Pautier P, Pignata S, Pérol D, González-Martín A, Berger R, et al. Olaparib plus bevacizumab as first-line maintenance in ovarian cancer. N Engl J Med 2019;381(25):2416–28. Ray-CoquardI PautierP PignataS PérolD González-MartínA BergerR Olaparib plus bevacizumab as first-line maintenance in ovarian cancer N Engl J Med 2019 381 25 2416 28 10.1056/NEJMoa191136131851799 Search in Google Scholar

[116] Mirza MR, Åvall Lundqvist E, Birrer MJ, dePont Christensen R, Nyvang GB, Malander S, et al. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. Lancet Oncol 2019;20(10):1409–19. MirzaMR Åvall LundqvistE BirrerMJ dePont ChristensenR NyvangGB MalanderS Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial Lancet Oncol 2019 20 10 1409 19 10.1016/S1470-2045(19)30515-7 Search in Google Scholar

[117] Drew Y, de Jonge M, Hong SH, Park YH, Wolfer A, Brown J, et al. An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC). Gynecol Oncol 2018;149(Suppl 1):246–7. DrewY de JongeM HongSH ParkYH WolferA BrownJ An open-label, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline-mutated (gBRCAm) platinum-sensitive relapsed (PSR) ovarian cancer (OC) Gynecol Oncol 2018 149 Suppl 1 246 7 10.1016/j.ygyno.2018.04.555 Search in Google Scholar

[118] Lampert EJ, Zimmer A, Padget M, Cimino-Mathews A, Nair JR, Liu Y, et al. Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study. Clin Cancer Res 2020;26(16):4268–79. LampertEJ ZimmerA PadgetM Cimino-MathewsA NairJR LiuY Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study Clin Cancer Res 2020 26 16 4268 79 10.1158/1078-0432.CCR-20-0056 Search in Google Scholar

[119] Konstantinopoulos PA, Waggoner S, Vidal GA, Mita M, Moroney JW, Holloway R, et al. Single-Arm Phases 1 and 2 Trial of Niraparib in Combination with Pembrolizumab in Patients with Recurrent Platinum-Resistant Ovarian Carcinoma. JAMA Oncol 2019;5(8):1141–9. KonstantinopoulosPA WaggonerS VidalGA MitaM MoroneyJW HollowayR Single-Arm Phases 1 and 2 Trial of Niraparib in Combination with Pembrolizumab in Patients with Recurrent Platinum-Resistant Ovarian Carcinoma JAMA Oncol 2019 5 8 1141 9 10.1001/jamaoncol.2019.1048 Search in Google Scholar

[120] Eskander RN, Ledermann JA, Birrer MJ, Fujiwara K, Gaillard S, Richardson E, et al. JAVELIN ovarian PARP 100 study design: Phase III trial of avelumab + chemotherapy followed by avelumab + talazoparib maintenance in previously untreated epithelial ovarian cancer. JCO 2019;37(8_Suppl). EskanderRN LedermannJA BirrerMJ FujiwaraK GaillardS RichardsonE JAVELIN ovarian PARP 100 study design: Phase III trial of avelumab + chemotherapy followed by avelumab + talazoparib maintenance in previously untreated epithelial ovarian cancer JCO 2019 37 8_Suppl 10.1200/JCO.2019.37.8_suppl.TPS9 Search in Google Scholar

[121] Farley J, Brady WE, Vathipadiekal V, Lankes HA, Coleman R, Morgan MA, et al. Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study. Lancet Oncol 2013;14(2):134–40. FarleyJ BradyWE VathipadiekalV LankesHA ColemanR MorganMA Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study Lancet Oncol 2013 14 2 134 40 10.1016/S1470-2045(12)70572-7 Search in Google Scholar

[122] Hew KE, Miller PC, El-Ashry D, Sun J, Besser AH, Ince TA, et al. MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer. Clin Cancer Res 2016;22(4):935–47. HewKE MillerPC El-AshryD SunJ BesserAH InceTA MAPK Activation Predicts Poor Outcome and the MEK Inhibitor, Selumetinib, Reverses Antiestrogen Resistance in ER-Positive High-Grade Serous Ovarian Cancer Clin Cancer Res 2016 22 4 935 47 10.1158/1078-0432.CCR-15-0534 Search in Google Scholar

[123] Konstantinopoulos PA, Barry WT, Birrer M, Westin SN, Cadoo KA, Shapiro GI, et al. Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial. Lancet Oncol 2019;20(4):570–80. KonstantinopoulosPA BarryWT BirrerM WestinSN CadooKA ShapiroGI Olaparib and α-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial Lancet Oncol 2019 20 4 570 80 10.1016/S1470-2045(18)30905-7 Search in Google Scholar

[124] Gupta GV, Fernandez YL, Roby K, Pathak H, Hirst J, Wilson AJ, et al. Entinostat enhances the efficacy of olaparib in preclinical models of ovarian cancer. Cancer Res 2019;(79)(13 Suppl) (Abstract 3501). GuptaGV FernandezYL RobyK PathakH HirstJ WilsonAJ Entinostat enhances the efficacy of olaparib in preclinical models of ovarian cancer Cancer Res 2019 79 13 Suppl (Abstract 3501). 10.1158/1538-7445.AM2019-3501 Search in Google Scholar

[125] Pulliam N, Fang F, Ozes AR, Tang J, Adewuyi A, Keer H, et al. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations. Clin Cancer Res 2018;24(13):3163–75. PulliamN FangF OzesAR TangJ AdewuyiA KeerH An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations Clin Cancer Res 2018 24 13 3163 75 10.1158/1078-0432.CCR-18-0204700371529615458 Search in Google Scholar

[126] D’ Andrea AD. Mechanisms of PARP inhibitor sensitivity and resistance. DNA Repair (Amst) 2018;71:172–6. D’ AndreaAD Mechanisms of PARP inhibitor sensitivity and resistance DNA Repair (Amst) 2018 71 172 6 10.1016/j.dnarep.2018.08.02130177437 Search in Google Scholar

[127] Drost R, Bouwman P, Rottenberg S, Boon U, Schut E, Klarenbeek S, et al. BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance. Cancer Cell 2011;20(6):797–809. DrostR BouwmanP RottenbergS BoonU SchutE KlarenbeekS BRCA1 RING function is essential for tumor suppression but dispensable for therapy resistance Cancer Cell 2011 20 6 797 809 10.1016/j.ccr.2011.11.01422172724 Search in Google Scholar

[128] Johnson N, Johnson SF, Yao W, Li YC, Choi YE, Bernhardy AJ, et al. Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance. Proc Natl Acad Sci U S A. 2013;110(42):17041–6. JohnsonN JohnsonSF YaoW LiYC ChoiYE BernhardyAJ Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance Proc Natl Acad Sci U S A 2013 110 42 17041 6 10.1073/pnas.1305170110380106324085845 Search in Google Scholar

[129] Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature 2008;451(7182):1116–20. SakaiW SwisherEM KarlanBY AgarwalMK HigginsJ FriedmanC Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers Nature 2008 451 7182 1116 20 10.1038/nature06633257703718264087 Search in Google Scholar

[130] Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, et al. Resistance to therapy caused by intragenic deletion in BRCA2. Nature 2008;451(7182):1111–5. EdwardsSL BroughR LordCJ NatrajanR VatchevaR LevineDA Resistance to therapy caused by intragenic deletion in BRCA2 Nature 2008 451 7182 1111 5 10.1038/nature0654818264088 Search in Google Scholar

[131] Quigley D, Alumkal JJ, Wyatt AW, Kothari V, Foye A, Lloyd P, et al. Analysis of circulating cell-free DnA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors. Cancer Discov 2017;7(9):999–1005. QuigleyD AlumkalJJ WyattAW KothariV FoyeA LloydP Analysis of circulating cell-free DnA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors Cancer Discov 2017 7 9 999 1005 10.1158/2159-8290.CD-17-0146558169528450426 Search in Google Scholar

[132] Pettitt SJ, Krastev DB, Brandsma I, Dréan A, Song F, Aleksandrov R, et al. Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance. Nat Commun 2018;9(1):1849. PettittSJ KrastevDB BrandsmaI DréanA SongF AleksandrovR Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance Nat Commun 2018 9 1 1849 10.1038/s41467-018-03917-2594562629748565 Search in Google Scholar

[133] Chapman JR, Barral P, Vannier JB, Borel V, Steger M, Tomas-Loba A, et al. RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection. Mol Cell 2013;49(5):858–71. ChapmanJR BarralP VannierJB BorelV StegerM Tomas-LobaA RIF1 Is Essential for 53BP1-Dependent Nonhomologous End Joining and Suppression of DNA Double-Strand Break Resection Mol Cell 2013 49 5 858 71 10.1016/j.molcel.2013.01.002359474823333305 Search in Google Scholar

[134] Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 2010;17(6):688–95. BouwmanP AlyA EscandellJM PieterseM BartkovaJ van der GuldenH 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers Nat Struct Mol Biol 2010 17 6 688 95 10.1038/nsmb.1831291250720453858 Search in Google Scholar

[135] Gupta R, Somyajit K, Narita T, Maskey E, Stanlie A, Kremer M, et al. DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity. Cell 2018;173(4):972–988.e23. GuptaR SomyajitK NaritaT MaskeyE StanlieA KremerM DNA Repair Network Analysis Reveals Shieldin as a Key Regulator of NHEJ and PARP Inhibitor Sensitivity Cell 2018 173 4 972 988 e23 10.1016/j.cell.2018.03.050810809329656893 Search in Google Scholar

[136] Choi YH, Yu AM. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des 2014;20(5):793–807. ChoiYH YuAM ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development Curr Pharm Des 2014 20 5 793 807 10.2174/138161282005140214165212634199323688078 Search in Google Scholar

[137] Schlacher K, Wu H, Jasin M. A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2. Cancer Cell 2012;22(1):106–16. SchlacherK WuH JasinM A distinct replication fork protection pathway connects Fanconi anemia tumor suppressors to RAD51-BRCA1/2 Cancer Cell 2012 22 1 106 16 10.1016/j.ccr.2012.05.015395474422789542 Search in Google Scholar

[138] Lomonosov M, Anand S, Sangrithi M, Davies R, Venkitaraman AR. Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein. Genes Dev. 2003;17(24):3017–22. LomonosovM AnandS SangrithiM DaviesR VenkitaramanAR Stabilization of stalled DNA replication forks by the BRCA2 breast cancer susceptibility protein Genes Dev 2003 17 24 3017 22 10.1101/gad.27900330525314681210 Search in Google Scholar

[139] Ray Chaudhuri A, Callen E, Ding X, Gogola E, Duarte AA, Lee JE, et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature 2016;535(7612):382–7. Ray ChaudhuriA CallenE DingX GogolaE DuarteAA LeeJE Replication fork stability confers chemoresistance in BRCA-deficient cells Nature 2016 535 7612 382 7 10.1038/nature18325495981327443740 Search in Google Scholar

[140] Rondinelli B, Gogola E, Yücel H, Duarte AA, van de Ven M, van der Sluijs R, et al. EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nat Cell Biol 2017;19(11):1371–8. RondinelliB GogolaE YücelH DuarteAA van de VenM van der SluijsR EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation Nat Cell Biol 2017 19 11 1371 8 10.1038/ncb362629035360 Search in Google Scholar

[141] Gallyas F Jr, Sumegi B, Szabo C. Role of Akt Activation in PARP Inhibitor Resistance in Cancer. Cancers (Basel). 2020;12(3):532. GallyasFJr SumegiB SzaboC Role of Akt Activation in PARP Inhibitor Resistance in Cancer Cancers (Basel) 2020 12 3 532 10.3390/cancers12030532713975132106627 Search in Google Scholar

[142] Aguilar-Quesada R, Muñoz-Gámez JA, Martín-Oliva D, Peralta A, Valenzuela MT, Matínez-Romero R, et al. Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition. BMC Mol Biol 2007;8:29. Aguilar-QuesadaR Muñoz-GámezJA Martín-OlivaD PeraltaA ValenzuelaMT Matínez-RomeroR Interaction between ATM and PARP-1 in response to DNA damage and sensitization of ATM deficient cells through PARP inhibition BMC Mol Biol 2007 8 29 10.1186/1471-2199-8-29186803517459151 Search in Google Scholar

[143] Tapodi A, Bognar Z, Szabo C, Gallyas F, Sumegi B, Hocsak E. PARP inhibition induces Akt-mediated cytoprotective effects through the formation of a mitochondria-targeted phospho-ATM-NEMO-Akt-mTOR signalosome. Biochem Pharmacol 2019;162:98–108. TapodiA BognarZ SzaboC GallyasF SumegiB HocsakE PARP inhibition induces Akt-mediated cytoprotective effects through the formation of a mitochondria-targeted phospho-ATM-NEMO-Akt-mTOR signalosome Biochem Pharmacol 2019 162 98 108 10.1016/j.bcp.2018.10.00530296409 Search in Google Scholar

[144] Staropoli N, Ciliberto D, Del Giudice T, Iuliano E, Cucè M, Grillone F, et al. The Era of PARP inhibitors in ovarian cancer: “Class Action” or not? A systematic review and meta-analysis. Crit Rev Oncol Hematol 2018;131:83–9. StaropoliN CilibertoD Del GiudiceT IulianoE CucèM GrilloneF The Era of PARP inhibitors in ovarian cancer: “Class Action” or not? A systematic review and meta-analysis Crit Rev Oncol Hematol 2018 131 83 9 10.1016/j.critrevonc.2018.08.01130293710 Search in Google Scholar

[145] Madariaga A, Bowering V, Ahrari S, Oza AM, Lheureux S. Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events. Int J Gynecol Cancer 2020;30(7):903–15. MadariagaA BoweringV AhrariS OzaAM LheureuxS Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events Int J Gynecol Cancer 2020 30 7 903 15 10.1136/ijgc-2020-001288739822732276934 Search in Google Scholar

[146] Liu Y, Meng J, Wang G. Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials. Drug Des Devel Ther 2018;12:3013–9. LiuY MengJ WangG Risk of selected gastrointestinal toxicities associated with poly (ADP-ribose) polymerase (PARP) inhibitors in the treatment of ovarian cancer: a meta-analysis of published trials Drug Des Devel Ther 2018 12 3013 9 10.2147/DDDT.S164553614720430271116 Search in Google Scholar

[147] Zhou JX, Feng LJ, Zhang X. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials. Drug Des Devel Ther 2017;11:3009–17. ZhouJX FengLJ ZhangX Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials Drug Des Devel Ther 2017 11 3009 17 10.2147/DDDT.S147726564832329075104 Search in Google Scholar

[148] Zibetti Dal Molin G, Westin SN, Msaouel P, Gomes LM, Dickens A, Coleman RL. Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors. Int J Gynecol Cancer 2020;30(1):89–93. Zibetti Dal MolinG WestinSN MsaouelP GomesLM DickensA ColemanRL Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors Int J Gynecol Cancer 2020 30 1 89 93 10.1136/ijgc-2019-00071431792084 Search in Google Scholar

[149] Ison G, Howie LJ, Amiri-Kordestani L, Zhang L, Tang S, Sridhara R, et al. FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy. Clin Cancer Res 2018;24(17):4066–71. IsonG HowieLJ Amiri-KordestaniL ZhangL TangS SridharaR FDA Approval Summary: Niraparib for the Maintenance Treatment of Patients with Recurrent Ovarian Cancer in Response to Platinum-Based Chemotherapy Clin Cancer Res 2018 24 17 4066 71 10.1158/1078-0432.CCR-18-004229650751 Search in Google Scholar